A clinical trial published in Lancet Oncology shows that combination immunotherapy significantly improves survival in melanoma patients with brain metastases. The seven-year study found 51% survival in first-line therapy patients, compared to 29% with single-agent treatment. Experts say this breakthrough could become the new standard of care for advanced melanoma.